Clinical Evidence: UK Weight Loss Results Comparison Data
UK Clinical Trial Evidence When Switching From Wegovy To Mounjaro
Understanding the clinical evidence behind both treatments is crucial when considering switching from Wegovy to Mounjaro in the UK. Wegovy demonstrated approximately 15% average weight loss at 68 weeks in the STEP 1 trial, with patients taking semaglutide alongside diet and exercise (Wilding et al., NEJM, 2021). The STEP 5 trial showed sustained weight loss of 15.2% at two years, indicating long-term effectiveness. Mounjaro's SURMOUNT trials showed different results, with the highest dose achieving approximately 22% average weight loss in clinical studies.
Both prescription-only medicines work through different mechanisms, which may influence your switching decision. Wegovy acts solely on GLP-1 receptors, whilst Mounjaro targets both GLP-1 and GIP receptors as a dual agonist. Your prescriber can evaluate your individual response to Wegovy and determine whether switching to Mounjaro's dual-action approach might be appropriate for your weight management goals.
Wegovy Pricing Structure For UK Patients Considering Switching
Before switching from Wegovy to Mounjaro UK patients should understand the current pricing for both options. Wegovy single pens range from £79.99 for the 0.25mg starter dose to £209.99 for the 2.4mg maintenance dose, with new customers applying code FIRST40 at checkout. Our Getting Started bundles provide convenience, such as the Intro Duo (0.25mg & 0.5mg) for £169.99, covering your first eight weeks. For patients on maintenance doses, the Consistency 2.4mg (×2) bundle costs £419.99, providing two months of treatment.
EverydayMeds also stocks comprehensive three-pen bundles for extended supply security. The Intro Trio (0.25mg, 0.5mg & 1mg) costs £299.99, covering your first 12 weeks of dose escalation. Returning customers benefit from code DOSE25 applied at checkout. Our GPhC-registered pharmacy (#9012878) ensures all pricing includes proper pharmaceutical oversight and clinical assessment requirements for this prescription-only medicine.
Published STEP Trial Results Supporting Switching Decisions From Wegovy To Mounjaro UK
The landmark STEP trials provide robust evidence for UK patients considering switching from Wegovy to Mounjaro. STEP 1 demonstrated that patients taking Wegovy alongside diet and exercise achieved approximately 15% average weight loss compared to 2.4% with placebo at 68 weeks. STEP 3, which included intensive behavioural therapy, showed approximately 16% average weight loss.
The SELECT cardiovascular outcomes trial revealed an additional benefit, with Wegovy demonstrating a 20% reduction in major cardiovascular events (HR 0.80). These results may influence your prescriber's recommendation when considering switching from Wegovy to Mounjaro UK, particularly if you have cardiovascular risk factors alongside weight management goals.
How Wegovy Works: GLP-1 Mechanism Before Switching To Mounjaro UK
Understanding Wegovy's mechanism is essential when considering switching from Wegovy to Mounjaro UK, as the treatments work differently. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics your body's natural fullness hormone. It reduces appetite by acting on brain appetite centres and promotes feeling of fullness after smaller meals. The medication may also reduce food cravings, supporting your dietary changes. Unlike Mounjaro's dual GLP-1/GIP action, Wegovy targets GLP-1 receptors exclusively. This single-target approach has proven effective in clinical trials, but some patients may respond better to Mounjaro's dual mechanism.
EverydayMeds Ordering Process For Patients Switching From Wegovy To Mounjaro UK
Our streamlined process supports patients switching from Wegovy to Mounjaro UK through comprehensive clinical assessment. Complete our 3-minute online questionnaire detailing your current Wegovy experience, response, and reasons for considering a switch. Your prescriber reviews your assessment within 3 working days (or 24 hours with express service), evaluating whether continuing Wegovy or switching to Mounjaro aligns with your treatment goals. Upon approval, we dispatch your medication via next-day delivery using temperature-controlled cold-chain logistics. Our GPhC-registered pharmacy ensures all prescription-only medicine requirements are met throughout the switching process. Both Wegovy and Mounjaro are available through the same clinical pathway, simplifying your transition between treatments.
Storage Considerations When Switching From Wegovy To Mounjaro UK
Storage requirements differ between treatments and may influence your decision when switching from Wegovy to Mounjaro UK. Wegovy requires refrigeration at 2-8°C before first use, but offers superior travel flexibility with 6 weeks at room temperature below 30°C once removed from the fridge. Mounjaro allows only 21 days at room temperature, making Wegovy more convenient for extended travel. Both use pre-filled FlexTouch pens for once-weekly injection, following identical dose escalation protocols. Wegovy's escalation progresses from 0.25mg through 0.5mg, 1mg, 1.7mg to 2.4mg maintenance over 16 weeks. This extended storage advantage may be relevant if your lifestyle involves frequent travel or if refrigeration access varies.
Comparative Effectiveness Analysis For UK Patients Switching From Wegovy To Mounjaro
Clinical evidence suggests different response patterns that may guide your decision when switching from Wegovy to Mounjaro UK. While both treatments require administration alongside a reduced-calorie diet and increased physical activity, their mechanisms may suit different patient profiles. Wegovy's single GLP-1 action provides proven cardiovascular benefits beyond weight loss, as demonstrated in the SELECT trial. Some patients who plateau on Wegovy may respond to Mounjaro's dual GLP-1/GIP mechanism.
Your prescriber will evaluate your individual response to Wegovy before recommending a switch to Mounjaro. Factors include current weight loss trajectory, side effect tolerance, and overall treatment satisfaction. Both treatments are available through EverydayMeds, allowing your prescriber to help determine which option best supports your weight management goals without requiring you to change pharmacy providers.
Complete Your Switching Assessment: Wegovy To Mounjaro UK Consultation
Ready to explore switching from Wegovy to Mounjaro UK through expert clinical guidance? Start your assessment at EverydayMeds today, where our prescribers can evaluate your current treatment response and determine the most appropriate next steps. New customers apply code FIRST40 at checkout, while returning customers use DOSE25 for immediate savings. Our comprehensive consultation covers your Wegovy experience, treatment goals, and suitability for continuing your current therapy versus switching to Mounjaro. With next-day delivery and ongoing clinical support, we make the transition process straightforward and medically supervised. Both treatments remain available through our secure online platform, ensuring continuity of care regardless of your prescriber's recommendation.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
